2025 United Kingdom Amyotrophic Lateral Sclerosis (Als) Treatment Revenue Opportunities Report
Description
The 2025 United Kingdom Amyotrophic Lateral Sclerosis (Als) Treatment Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Amyotrophic Lateral Sclerosis (ALS) Treatment by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in ALS treatment development in the United Kingdom market are Biogen Inc., Sanofi, Mitsubishi Tanabe Pharma Corporation, and BrainStorm Cell Therapeutics. Biogen is a leader with its gene-targeting therapy QALSODY® (tofersen), aimed at the genetic SOD1-ALS form, receiving a positive EMA opinion in 2024. Sanofi emphasizes innovation through collaborations and research in ALS therapies, significantly broadening treatment options. Mitsubishi Tanabe Pharma and BrainStorm Cell Limited also drive market growth via strategic partnerships and clinical programs targeting ALS progression.
Additionally, Trace Neuroscience, a UCL spinout, has emerged as an innovative UK-based biopharma with $101 million funding to develop genomic therapies targeting UNC13A protein loss in ALS cases. This funding highlights significant UK academic-industry collaboration aimed at addressing neurodegeneration in ALS. These companies benefit from the UK’s advanced healthcare infrastructure, regulatory support, and ongoing clinical trials like EXPERTS-ALS, reinforcing the region's active role in ALS therapeutic advancement.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Amyotrophic Lateral Sclerosis (ALS) Treatment by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in ALS treatment development in the United Kingdom market are Biogen Inc., Sanofi, Mitsubishi Tanabe Pharma Corporation, and BrainStorm Cell Therapeutics. Biogen is a leader with its gene-targeting therapy QALSODY® (tofersen), aimed at the genetic SOD1-ALS form, receiving a positive EMA opinion in 2024. Sanofi emphasizes innovation through collaborations and research in ALS therapies, significantly broadening treatment options. Mitsubishi Tanabe Pharma and BrainStorm Cell Limited also drive market growth via strategic partnerships and clinical programs targeting ALS progression.
Additionally, Trace Neuroscience, a UCL spinout, has emerged as an innovative UK-based biopharma with $101 million funding to develop genomic therapies targeting UNC13A protein loss in ALS cases. This funding highlights significant UK academic-industry collaboration aimed at addressing neurodegeneration in ALS. These companies benefit from the UK’s advanced healthcare infrastructure, regulatory support, and ongoing clinical trials like EXPERTS-ALS, reinforcing the region's active role in ALS therapeutic advancement.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
